Discovering ZSCAN21: A Protein Targeted for Cancer and Other Diseases

Target Name: ZSCAN21

NCBI ID: G7589

ZSCAN21

Discovering ZSCAN21: A Protein Targeted for Cancer and Other Diseases

ZSCAN21 (Zipro1) is a drug target and a biomarker that is being studied for its potential utility in treating various diseases, including cancer. ZSCAN21 is a type of scaffold protein that is found in various cell types in the body, including blood vessels, neurons, and immune cells.

The discovery of ZSCAN21 comes from a research team led by Dr. Peter J. halfpenny at the University of Cambridge, who identified the protein in 2003. ZSCAN21 is a transmembrane protein that is characterized by its unique structure, which consists of a long extracellular tail and a short intracellular tail.

The intracellular tail of ZSCAN21 is known as the Z-tail and is thought to play a key role in its biology. The Z-tail is composed of a unique domain that is involved in interactions with various signaling pathways, including the TGF-β pathway. TGF-β is a well-known protein that is involved in cell growth, differentiation, and survival.

Several studies have suggested that ZSCAN21 may be a drug target due to its involvement in the TGF-β pathway. The TGF-β pathway is a critical signaling pathway that is involved in various cellular processes, including cell growth, differentiation, and survival. It is thought to play a key role in the development and progression of many diseases, including cancer.

In addition to its involvement in the TGF-β pathway, ZSCAN21 has also been shown to be involved in several other signaling pathways, including the PI3K/Akt signaling pathway and the NF-kappa-B signaling pathway. The PI3K/Akt signaling pathway is involved in cell survival and angiogenesis, while the NF-kappa-B signaling pathway is involved in inflammation and cellular signaling.

The ZSCAN21 protein has also been shown to be involved in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, several studies have suggested that ZSCAN21 may be involved in the development and progression of breast cancer, by regulating the activity of the TGF-β pathway.

In addition to its potential as a drug target, ZSCAN21 has also been shown to be a valuable biomarker for several diseases. For example, ZSCAN21 has been shown to be involved in the diagnosis of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been used as a biomarker for evaluating the effectiveness of anti-inflammatory therapies in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Overall, the discovery of ZSCAN21 has significant implications for our understanding of the biology of disease and the potential for new treatments. Further research is needed to fully understand the role of ZSCAN21 in disease and to develop effective treatments based on its potential as a drug target and biomarker.

Protein Name: Zinc Finger And SCAN Domain Containing 21

Functions: Strong transcriptional activator (By similarity). Plays an important role in spermatogenesis; essential for the progression of meiotic prophase I in spermatocytes (By similarity)

The "ZSCAN21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets